CXCL12 and inflammatory skin disease: In this sense, it has been recently demonstrated that an endogenous CXCR4 antagonist reduced skin inflammation in an AD mouse model, demonstrating a role for the CXCR4/CXCL12 axis in AD, as well as showing a potential role for CXCR4-antagonizing agents as therapeutic options in skin inflammatory diseases (70).